Accent Microcell Ltd Q1 FY27 Earnings Analysis

- FY27 growth expected primarily from Phase 1 of Unit 3 and premium excipient product range launched in H2 FY26. - Phase 2 of Unit 3 expected to go commercial by March 2027, adding further manufacturing revenue. - Trading volumes currently elevated to retain customer base; expected to reduce once Phase 1 and Phase 2 capacities fully utilized. - Revenue from Phase 1 anticipated around ₹340-350 crore by end of FY27 but not at peak capacity in first year. - Export revenue share likely to increase due to premium products and MCC Spheres production targeting global markets. - Gradual increase in premium product revenue share expected, reaching ~16-17% in FY27 from 13% in FY26. - Working capital and borrowings unlikely to increase substantially; funding mainly through rights issue and internal accruals for scaling. - Longer-term growth driven by subsequent phases (up to Phase 6) funded internally without major debt.

- Management refrained from giving precise forward-looking guidance on profit margins or earnings, citing the premature nature of such forecasts (Page 13). - Blended profit margins are expected to improve by around 2-3 percentage points with commercialization of more premium range products (Page 13). - EBITDA margins are anticipated to increase post the commissioning of Phase 2 capacity (Page 13). - Trading volumes, which currently depress margins, are expected to reduce substantially after Phase 1 and Phase 2 become fully operational, potentially improving profitability (Pages 10, 13). - Revenue growth is to be driven primarily by Phase 1; peak manufacturing revenue from Phase 1 is projected around Rs. 150-160 crore per annum but actual capacity utilization ramp-up will be gradual (Page 10). - No quantified revenue or EPS guidance was provided for FY27-29; management will share installed capacities but not revenue figures (Page 13). - Working capital and borrowings are expected to remain stable without significant increase, supporting financial health (Pages 17, 26).

- Accent Microcell Ltd. is expanding capacity with Unit 3 in a phased manner: - Phase 1 targets premium excipient products, enhancing blended profit margins. - Phase 2 focuses on MCC production, primarily for export markets and Indian MNCs. - Future phases planned up to Phase 6, with internal accruals expected to fund expansion without outside debt. - Right issue and internal cash flows are funding Phase 1 and Phase 2; no new debt planned currently. - Working capital and term loan limits with Kotak Mahindra Bank are available if needed, but no immediate borrowing plans. - MCC Spheres capacity is about 100 tons per month, with gradual ramp-up aligned with customer demand and new MCC capacity. - Expansion targets increased export sales, premium product mix growing from 13% to approx. 16-17% by FY27. - Commercialization timelines impacted by regulatory delays but expected to be addressed by end of FY27.

- No new debt fundraising planned for Phase 1 and Phase 2; funding will be through internal accruals and rights issue. (Page 23) - Management does not foresee any new debt in the near future. (Page 23) - Working capital and term loan limits with Kotak Mahindra Bank are available for utilization if required, but no immediate plans for further borrowing. (Pages 22, 26) - For future phases beyond Phase 2 (up to Phase 6), internal accruals are expected to suffice; no current plans for debt fundraising. (Page 26) - Management opted for equity (rights issue) over debt earlier to avoid initial leverage and gain competitive advantages. (Page 22) - Any fundraising decisions will be guided by business needs and regulatory requirements, with positive consideration of investors' inputs. (Page 26)

- Accent Microcell Ltd. stated they have an overall order book for premium products covering at least 3 to 4 months for both export and domestic markets. - In the context of MNC Indian customers, the approval process is ongoing with expected approvals in the near future, which would likely increase domestic revenue in the next year. - No specific quantified figures or value of the current order book were disclosed. - Orders related to premium product range are active and provide visibility for a few months ahead. - The company aims to ramp up production phases (Phase 1 and Phase 2) to meet increasing demand reflected in the order books.